Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home


Related trials

ACCELERATE, 2015 - evacetrapib vs placebo

IMPROVE-IT, 2014 - ezetimibe vs control

dal-OUTCOMES, 2012 - dalcetrapib vs placebo

AIM-HIGH, 2011 - niacin vs placebo (on top statin)

dal-VESSEL, 2011 - dalcetrapib vs placebo

ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)

SHARP, 2010 - ezetimibe+simvastatin vs placebo

SEARCH, 2010 - simvastatin high dose vs simvastatin

ARBITER-HALTS 6, 2010 - ezetimibe vs niacin

DEFINE, 2010 - anacetrapib vs placebo

Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)

ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe

Emmerich, 2009 - etofibrate vs placebo

ARBITER 2, 2009 - niacin vs placebo (on top statin)

SANDS, 2008 - aggressive treatment vs standard teatment

JUPITER, 2008 - rosuvastatin vs placebo

GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo

Tuttle, 2008 - low fat diet vs mediterranean-style diet

RADIANCE 1, 2007 - torcetrapib vs placebo (on top of atorvastatin)

ILLUSTRATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

CORONA, 2007 - rosuvastatin vs placebo

METEOR, 2007 - rosuvastatin vs placebo

Krum, 2007 - rosuvastatin vs placebo

RADIANCE 2, 2007 - torcetrapib vs placebo (on top of atorvastatin)

ILLUMINATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of HDL increasing drugs
  • All clinical trials of gemfibrozil
  •  
     LOCAT study, 1997 TRC10781 
    download pdf: gemfibrozil | cholesterol lowering intervention for cardiovascular prevention

    Treatments

    Studied treatment gemfibrozil 1200 mg/d
    Control treatment placebo

    Patients

    Patients post-coronary bypass men, who had an HDL cholesterol concentration < or = 1.1 mmol/L and LDL cholesterol < or = 4.5 mmol/L
    Baseline characteristics
    Age (mean), yrs 60 
    Women (%) 0% 
    Total cholesterol (mmol/l) 5.2 mmol/L 
    Diabetes(%) 0% 

    Method and design

    Randomized effectives 197 / 198 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 32 months
    Geographic area Germany
    Primary endpoint diameters


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Coronary event

    7 / 197
    7 / 198
    classic 1,01 [0,36;2,81]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Coronary event 7 / 197 (3,6%) 7 / 198 (3,5%) 1,01 [0,36;2,81]   12545
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 12545: Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic VEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.Lancet 2010 May 10;:
  • 0:

  • Endpoint studied treat. control treat. mean diff
    total cholesterol (at 1 y) 4,83 (0,63) 5,48 (0,68) -0,65 [-0,779;-0,52]
    HDL (at 1 y) 0,98 (0,17) 0,88 (0,15) 0,10 [0,068;0,13]
    LDL 3,39 (0,56) 3,83 (0,59) -0,44 [-0,553;-0,33]

    Absolute risk reduction (for a follow-up of 32 months)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Coronary event 3,55% 3,54% 0,02%

    Meta-analysis of all similar trials:

    cholesterol lowering intervention in cardiovascular prevention for patients with prior MI or with CHD

    cholesterol lowering intervention in cardiovascular prevention for all chronical situations

    HDL increasing drugs in cardiovascular prevention for all type of patients



    Reference(s)

    TrialResults-center ID TRC10781
    Trials register # NA
    • Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesäniemi YA, Pasternack A, Taskinen MR. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.. Circulation 1997;96:2137-43
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels